{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-017648","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2024-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.063842+00:00","generated_at":"2026-06-01T12:09:27.974864+00:00","sec_items":["1.01","5.02","1.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CervoMed names William Elder as CFO; William Tanner departs to consulting role","bullets":["William Elder appointed CFO effective June 1, 2024, succeeding William Tanner; Elder continues as General Counsel and Corporate Secretary.","Outgoing CFO William Tanner to serve as consultant through Dec 2025; receives $162,000 severance plus prorated bonus and extended stock option vesting.","Elder's compensation: base salary $429,000, target bonus 35% of base; severance includes 9 months salary on non-cause termination.","Company expects RewinD-LB Phase 2b enrollment completion in Q2 2024, topline efficacy results in Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-017648","json":"https://secwatch.observer/filing/0001437749-24-017648.json","markdown":"https://secwatch.observer/filing/0001437749-24-017648.md","text":"https://secwatch.observer/filing/0001437749-24-017648.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924017648/0001437749-24-017648-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924017648/crvo20240520_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T12:09:27.974864+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"babb346485","claim":"William Elder was appointed as Chief Financial Officer at CervoMed Inc..","evidence_excerpt":"appointed William Elder, the Company’s current General Counsel, Corporate Secretary and Acting Principal Financial Officer, to serve as the Company’s Chief Financial Officer, effective June 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924017648/0001437749-24-017648-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"e4504a705d","claim":"William Tanner was terminated as Chief Financial Officer at CervoMed Inc..","evidence_excerpt":"Dr. Tanner’s employment with the Company will terminate effective May 31, 2024, and, effective June 1, 2024, Dr. Tanner will begin service as a consultant to the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924017648/0001437749-24-017648-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}